Faculty Bibliography

The radio frequency ablation segmentation tool (RFAST) is a software application developed using the National Institutes of Health's medical image processing analysis and visualization (MIPAV) API for the specific purpose of assisting physicians in the planning of radio frequency ablation (RFA) procedures. The RFAST application sequentially leads the physician through the steps necessary to register, fuse, segment, visualize, and plan the RFA treatment. Three-dimensional volume visualization of the CT dataset with segmented three dimensional (3-D) surface models enables the physician to interactively position the ablation probe to simulate burns and to semimanually simulate sphere packing in an attempt to optimize probe placement. This paper describes software systems contained in RFAST to address the needs of clinicians in planning, evaluating, and simulating RFA treatments of malignant hepatic tissue.

The factor structure of the Bulimia Test--Revised (BULIT-R) was investigated using confirmatory factor analysis (CFA) and exploratory factor analysis (EFA). The sample consisted of 2,671 female college students (African American, Asian American, Caucasian American, and Latino American). Reliability coefficients were excellent across groups. African Americans scored significantly lower on the BULIT-R than Caucasian Americans. Across groups, CFA and EFA results suggest a six-factor solution is most appropriate. Consistent across groups were factors representing bingeing, body image, purging, and extreme weight loss behaviors, while few differences were observed across groups. These findings suggest that the measure is reliable and valid for use with diverse ethnic groups. Future research should focus on culturally salient psychological correlates of disordered eating in diverse ethnic groups

In the study, which independent experts said was the most conclusive to examine the role of condoms in preventing infection with the virus, women whose male partners used condoms every time they had sexual intercourse had less than half the rate of infection than women whose partners used condoms less than 5 percent of the time. The study was conducted among students at the University of Washington in Seattle. In 2000, four government agencies convened a panel of condom experts to determine the medical accuracy of condom labels. The panel concluded that there was inadequate information about condom use in reducing the risk of all sexually transmitted infections except for the AIDS virus and, among men, gonorrhea, an editorial accompanying the journal article said

In the study, which independent experts said was the most conclusive to examine the role of condoms in preventing infection with the virus, women whose male partners used condoms every time they had sexual intercourse had less than half the rate of infection as did women whose partners used condoms less than 5 percent of the time. The study 'provided a very clear answer' to the question of the protective benefits of condoms and papillomavirus infection, said Dr. James R. Allen, president of the American Social Health Association, an organization in Research Triangle Park, N.C., dedicated to the prevention of sexually transmitted infections. Allen said he was not involved in the study

In the study, which independent experts said was the most conclusive to examine the role of condoms in preventing infection with the virus, women whose male partners used condoms every time they had sexual intercourse had less than half the rate of infection as did women whose partners used condoms less than 5 percent of the time. In 2000, four government agencies convened a panel of condom experts to determine the medical accuracy of condom labels in describing their effectiveness in preventing papillomavirus and other sexually transmitted diseases. The researchers used certain statistical measures to determine the findings in the study. For example, no malignant or precancerous cervical lesions were detected in 32 patient years at risk among women reporting 100 percent condom use by their partners. That compared with 14 such lesions in 97 patient years at risk among women whose partners did not use condoms or who used them less consistently

Reporting in The New England Journal of Medicine, the study's authors said they had recruited 158 scleroderma patients who had early signs of lung damage. The patients, drawn from 13 hospitals in this country, agreed to be assigned randomly to one of two groups, without knowing which one. One group of 79 was to take Cytoxan pills daily for a year. An equal number were to take a placebo, or dummy pill, also for a year. Both groups were monitored for a second year. Many doctors already prescribe Cytoxan for scleroderma patients, in part because earlier, less scientifically rigorous studies hinted at its benefit. But until now no drug for scleroderma patients with lung damage has proved effective in a scientifically controlled study, the type of research that scientists consider the gold standard for assessing benefits and safety of therapies, Dr. [Philip J. Clements] said in an interview